At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,333 enrolled
Drug / intervention
QIVc +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate Safety and Immunogenicity of Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and Cell-Based Trivalent Subunit Influenza Virus Vaccines in Subjects Ages ≥4 Years to < 18 Years
In Brief
A Phase 3 clinical trial evaluating QIVc, TIV1c, and 1 other intervention for Influenza. Completed, enrolled 2,333 participants across 88 sites.
Detailed Summary
Evaluate safety and immunogenicity of three influenza vaccines in children ages greater than 4 years old to less than 18 years old.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedNov 2013
Primary CompletionAug 2014
TodayJul 2026
First PostedNov 25, 2013
Enrollment StartNov 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.6 years ago
Interventions
QIVcbiological
Novartis Investigational Quadrivalent Vaccine
TIV1cbiological
Licensed Influenza Vaccine
TIV2cbiological
Novartis Investigational Vaccine